SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after its CEOs anniversary message prompted renewed speculation about a potential buyout, alongside anticipation for the final analysis of its Phase 3 REGAL leukemia trial, which requires 80 events and was last reported at 78. Traders disagree on whether the message and prolonged trial timeline signal favorable data or a deal; neither a buyout nor a trial outcome has been confirmed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rises amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about oil-supply disruptions. Traders are divided over whether geopolitical risks will keep prices elevated or whether Iran-US deal headlines and Russian supply relief will unwind the risk premium; some also question the reliability of the headlines.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows has focused discussion on waning confidence in Trump ahead of the midterms and concerns about Truth Socials engagement and the companys underlying business. Bearish traders see room for further declines, while some view the selloff as an opportunity for a short-term bounce.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff and weak performance versus peers as traders debate neocloud financing risks and broader concerns about AI infrastructure spending. The co-CEOs statement that data centers carry no debt and customer prepayments help fund GPU costs has reassured some investors, while others remain concerned about execution and the stocks continued weakness.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price weakness and underperformance versus the biotech sector despite revenue growth from ORLADEYO. Traders are split between viewing the valuation as overly discounted and worrying that managements acquisition-focused strategy, dilution and HAE competition leave the stock dependent on future navenibart and pipeline results.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is drawing attention amid HSBCs bearish assessment and concerns about heavy debt, borrowing costs and access to financing for its AI infrastructure expansion. Traders are divided between expecting further downside and betting on a rebound or short squeeze; some bulls point to reported GPU price increases as evidence of demand and pricing power.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a possible US-Iran dealand a pullback in oil pricesare widely cited as drivers of QQQs sharp rebound and volatile swings. Traders disagree over whether the rally is durable or a headline-driven bull trap, while upcoming big-tech earnings and AI-sector weakness add uncertainty.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound from recent lows and its struggle to clear near-term resistance are driving discussion, with traders debating whether the move can extend or fade into another pullback. Bulls see potential for a short squeeze, while skeptics call the bounce a trap and point to weak demand and macro uncertainty.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

A sharp selloff ahead of Robinhoods upcoming quarterly results is driving discussion, with traders pointing to broader risk-off pressure and analyst caution while debating whether the decline is overdone. Bearish posts focus on continued selling and weak price action, while some traders see support levels as a potential buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gland Pharma Secures USFDA Tentative Approval for Generic Lumify Eye Drops

Hyderabad: Gland Pharma Limited has announced that it … the United States. Gland Pharma , headquartered in Hyderabad, is a pharmaceutical company primarily focused … powders, infusions, oncology drugs , and ophthalmic solutions. Gland Pharma is also known …

Gland Pharma Names Dr Jitendra Gangwal Vice President, Research & Development

New Delhi: Gland Pharma has appointed Dr … institutions and leading Indian pharmaceutical companies. Over the course … . Prior to joining Gland Pharma , Dr. Gangwal was associated … . Reddy’s Laboratories, Glenmark Pharmaceuticals , Alkem Laboratories, and FDC …

Brief India: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains and more

In this briefing: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base 1. Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains Aditya Infotech Ltd (6596564Z IN) (AIL) raised around US$151m in its IPO in August 2025. The lockup on its pre-IPO investors is set to expire soon. AIL is a CCTV/video surveillance provider company offering a range of advanced video security and surveillance products, technologies and solutions for enterprise and consumer segments under its CP PLUS brand. In this note, we will talk about the lockup dynamics and possible placement. 2. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation.

Brief India: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD and more

In this briefing: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength 1. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD We initiate coverage on LG Electronics India (LG) with an ADD rating and a TP of INR 1,545 per share, valuing it at 38x Mar-28E AEPS We like LG for its market leadership in core product categories, strong brand equity, consistent technological innovations and product launches, healthy balance sheet, robust return ratios, and low working capital needs LG is a leading player in washing machines, refrigerators, panel televisions, and inverter ACs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense and more

In this briefing: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength Primer: Jammu & Kashmir Bank (JKBK IN) - Jan 2026 Exencial Industry Tidings 1. Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Domestic Market Share & Profitability Outlook: Domestic demand witnessed a sharp inflection in Q3FY26 following the government’s landmark GST reduction, which catalysed industry growth to ~20.5% YoY versus a decline of ~0.4% in H1FY26. MSIL outperformed the industry with domestic volume growth of ~22%, supported by strong traction across small cars and SUVs. Management highlighted a revival in the small car segment, which transitioned from a “red zone” of negative growth to healthy expansion, aided by improved affordability and a 7% rise in first-time buyers, particularly upgrades from two-wheelers.

Gland Pharma Shares Surge Over 9%, Q3 FY26 Profit Rises 28% To ₹261 Crore

Gland Pharma shares surged over 9 percent after Q3 FY26 profit rose 28 percent and revenue grew 23 percent. Strong product launches, higher R&D spending, and heavy trading volumes boosted investor sentiment.The strong stock movement came after the Hyderabad-based drug maker announced its financial results for the third quarter of FY26 after market hours on Wednesday.

Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution

… Regulations, 2015, Gland Pharma stated that the USFDA approval … United States market. Gland Pharma , established in 1978 and … injectable and ophthalmic-focused pharmaceutical company with operations across … in India. Gland Pharma stated that the approval …

These two companies will sell shovels during India’s semaglutide gold rush

Shaily Engineering Plastics Ltd and Gland Pharma Ltd, involved in the making and filling of injectable pens for semaglutide, stand to win big as patients will need these devices irrespective of which brand of the drug they choose.

Brief India: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale and more

In this briefing: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Westlife Foodworld Ltd - Resilience Amid Demand Softness; Maintain BUY Auto Monthly Sales Volume - October 2025 NOCIL Ltd - Pricing Pressure Continues; Global Uncertainties Adding to the Woes 1. PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale PVR Inox is piloting a full-service "dine-in" cinema concept in Bengaluru, while management confirms a major strategic shift towards an asset-light (FOCO) model for new screen expansion. The dine-in is a defensive move to protect premium Spend Per Head (SPH) against OTT, while the asset-light pivot is move to fix the balance sheet and scale in Tier-2/3. The company is re-engineering its business to be less dependent on its own capital, but its profitability remains entirely dependent on the one thing it cannot control: the content pipeline . 2. Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,487 Cr in Q2FY26, marking a 5.8% YoY growth, in line with our estimates.

Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch

… and patented drugs entering … pharma space include the likes of Natco Pharma , Laurus Labs, Alembic Pharma , Sun Pharma … , Gland Pharma , Ajanta Pharma , and Glenmark Pharmaceuticals … of Indian pharmaceutical exports. …

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.

Gland Pharma Ltd.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

Equity

Bearish Sentiment

Healthcare stocks in India fell on Friday as investors weighed the impact of U.S. President Donald Trump’s move to impose a 100% tariff on branded and patented drugs starting Oct. 1.&nbsp;The measure, announced in late-night Truth Social posts, exempts only those manufacturers with U.S. plants that are already under construction or have broken ground.The Nifty Healthcare index fell 1.2% on Thursday, with 18 of its 20 components trading lower.&nbsp;IPCA Laboratories remained unchanged, while Torrent Pharma rose 0.01%.Analyst ViewSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/ra_vishaltrehan">Vishal Trehan</a> said Gland Pharma is the most exposed, given its lack of a U.S. manufacturing footprint and reliance on branded or patented formulations.&nbsp;<stembedurl>https://stocktwits.com/ra_vishaltrehan/message/630078378</stembedurl>He noted that Syngene International, Piramal Pharma, and Zydus Lifesciences stand to benefit from their contract manufacturing models and biologics portfolios, which are less tariff-sensitive.Trehan also pointed out that companies with a large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion.Trump’s Pharma TariffsThe announcement builds on Trump’s escalating trade measures aimed at repatriating drug manufacturing. Last month, he outlined a phased plan, beginning with a “small tariff” on imported drugs, before lifting duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had earlier been excluded from his reciprocal tariff program, but the new rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, with generic drugs remaining exempt.What Is The Retail Mood?On Stocktwits, retail sentiment for Piramal Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories was ‘bearish’ amid ‘normal’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/GLAND.NSE">Gland Pharma</a> has risen 6.5%, while&nbsp;<a href="https://stocktwits.com/symbol/SYNGENE.NSE">Syngene International</a> is down 29.1%,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a> has slipped 25.9%,&nbsp;<a href="https://stocktwits.com/symbol/ZYDUSLIFE.NSE">Zydus Lifesciences</a> is up 1.8%,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s Laboratories</a> is down 7.2%, and&nbsp;<a href="https://stocktwits.com/symbol/BIOCON.NSE">Biocon</a> has fallen 6.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Current Price	3,030.00
Prev Close	3,035.00
Open	3,046.10
Dividend Yield	1.18%
50-Day Moving Average	2,942.35
Beta	-0.06
Avg. Volume	623,946.81
PE Ratio	44.08

52-Week High	3,171.00
52-Week Low	1,573.60
Market Capitalization	499.53B
EPS (Annual)	62.35
Price to Book	4.80
Revenue Per Employee	14.78M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLAND.NSE Fundamentals